|
|
Сonditions and diseases
AIDS/HIV ALS Alzheimer's Disease Anemia Anti-Aging Treatment Arterial Hypertension Autism Cancer Diabetes Treatment Eye Diseases Idiopathic Encephalopathy Ischemic Heart Disease Liver Diseases MD Treatment Multiple Sclerosis Treatment Parkinson Treatment Rheumatoid Arthritis SMA Ulcerative Colitis. Crohn’s Disease
News about stem cells
Stem cell treatment protects bone marrow from damaging chemotherapy effects in cancer patients
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
New Approach to Treating Muscular Dystrophy With Stem Cells
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
A New Brain Stem Cell Discovered
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
All news
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
Transplantation of fetal cell suspensions in complex treatment of patients with osteogenic sarcoma
Smikodub A.I., Radzievskaya L.V., Bendyug G.D., Glukhovskaya I.Yu.
Cell Therapy Clinic of National Medical University and EmCell Embryonic Tissues Center, Research Institute of Oncology and Radiology
The timely and complete chemotherapeutic treatment of many tumors may be restricted by the strong depressive effect of cytostatic preparations.
Correction of hematopoietic and immune disorders is possible through transplantation of hemopoietic cell suspensions.
In this study, we used cell suspensions of human embryonic liver for complex treatment of patients with osteogenic sarcoma and nephroblastoma. The objective of the study in was the improvement of antitumor treatment program through prevention or elimination of hematopoietic and immunological disorders.
19 children aged from 2 to 15 were observed (14 with osteogenic sarcoma, and 5 with nephroblastoma). The cryopreserved human embryonic liver cells of 7-12 weeks of gestation were transplanted. Suspensions were administered intravenously, dropwise, in volume of 1 to 4 ml; nucleated cell count was 30–50x106/ml; CFU-GEMM, 0.5–9x103.
The efficiency of transplantation of fetal cell suspensions (FCS) was evaluated according to patient’s condition, erythrocyte count, Hb, leukocytes, T- and B-lymphocytes, and their subpopulations.
In 12 patients, cytostatic leukopenia was observed before the transplantation. After the transplantation of FCS, statistically reliable increase leukocytesof leukocyte count and absoluteamount segment-nucleated neutrophils was observed from the 10th day. Levels of Hb and erythrocytes in patients with osteogenic sarcoma was relatively stable prior to and after transplantation, and did not require any additional correction. In patients with nephroblastoma, anemia were observed prior to transplantation, and statistically reliable increase in Hb and erythrocyte values, by the 7th day from FCS transplantation. Further programmed chemotherapy in both groups of patients was carried out during 2 to 3 months, timely and complete; in so doing, blood counts remained stable.
Also observed were positive changes of cell immunity values: increase in absolute and relative counts of lymphocytes (CD3), T-helpers (CD4), CD4/CD8 ratio, and NK-cells was noted on the 7th day.
14th Congress of Therapeutists, 1998.
Cell Therapy Clinic of National Medical University and EmCell Embryonic Tissues Center, Research Institute of Oncology and Radiology
The timely and complete chemotherapeutic treatment of many tumors may be restricted by the strong depressive effect of cytostatic preparations.
Correction of hematopoietic and immune disorders is possible through transplantation of hemopoietic cell suspensions.
In this study, we used cell suspensions of human embryonic liver for complex treatment of patients with osteogenic sarcoma and nephroblastoma. The objective of the study in was the improvement of antitumor treatment program through prevention or elimination of hematopoietic and immunological disorders.
19 children aged from 2 to 15 were observed (14 with osteogenic sarcoma, and 5 with nephroblastoma). The cryopreserved human embryonic liver cells of 7-12 weeks of gestation were transplanted. Suspensions were administered intravenously, dropwise, in volume of 1 to 4 ml; nucleated cell count was 30–50x106/ml; CFU-GEMM, 0.5–9x103.
The efficiency of transplantation of fetal cell suspensions (FCS) was evaluated according to patient’s condition, erythrocyte count, Hb, leukocytes, T- and B-lymphocytes, and their subpopulations.
In 12 patients, cytostatic leukopenia was observed before the transplantation. After the transplantation of FCS, statistically reliable increase leukocytesof leukocyte count and absoluteamount segment-nucleated neutrophils was observed from the 10th day. Levels of Hb and erythrocytes in patients with osteogenic sarcoma was relatively stable prior to and after transplantation, and did not require any additional correction. In patients with nephroblastoma, anemia were observed prior to transplantation, and statistically reliable increase in Hb and erythrocyte values, by the 7th day from FCS transplantation. Further programmed chemotherapy in both groups of patients was carried out during 2 to 3 months, timely and complete; in so doing, blood counts remained stable.
Also observed were positive changes of cell immunity values: increase in absolute and relative counts of lymphocytes (CD3), T-helpers (CD4), CD4/CD8 ratio, and NK-cells was noted on the 7th day.
14th Congress of Therapeutists, 1998.